Brain metastases: a medical neuro-oncology perspective

References

• Khuntia D, Brown P, Li J, Mehta M. Whole brain radiotherapy in the management of brain metastasis. J. Clin. Oncol.24(8), 1295–1304 (2006).
   PubMed Web of Science ®Google Scholar
• Langer CJ, Mehta M. Current management of brain metastases, with a focus on systemic options. J. Clin. Oncol.23(25), 6207–6219 (2005).
   PubMed Web of Science ®Google Scholar
• Norden AD, Wen PY, Kesari S. Brain metastases. Curr. Opin. Neurol.18(6), 279–292 (2005).
   Google Scholar
• Posner J. Management of brain metastases. Revue Neurologique (Paris)148(6–7), 477–487 (1992).
   PubMed Web of Science ®Google Scholar
• Zimm S, Wampler GL, Stablein D et al. Intracerebral metastases in solid-tumor patients: natural history and results of treatment. Cancer48, 384–394 (1981).
   PubMed Web of Science ®Google Scholar
• Posner JB. Brain metastases: 1995. A brief review. J. Neuro Oncol.27, 287–293 (1996).
   Google Scholar
• Chang JE, Robins HI, Mehta MP. Therapeutic advances in the treatment of brain metastases. Clin. Adv. Hematol. Oncol.5(1), 54–64 (2007).
   Google Scholar
• Barnholtz-Sloan J, Sloan A, Davis F et al. Incidence proportions of brain metastases in patients diagnosed (1973–2001) in the Metropolitan Detroit Cancer Surveillance System. J. Clin. Oncol.22(14), 2865–2872 (2004).
   PubMed Web of Science ®Google Scholar
• Suh JH, Chao ST, Vogelbaum MA. Management of brain metastases. Curr. Neurol. Neurosci. Rep.9(3), 223–230 (2009).
   Google Scholar
• Gaspar LE, Chansky K, Albain KS et al. Time from treatment to subsequent diagnosis of brain metastases in stage III non-small-cell lung cancer: a retrospective review by the Southwest Oncology Group. J. Clin. Oncol.25(13), 2955–2961 (2005).
   Google Scholar
• Pottgen C, Eberhardt W, Grannass A et al. Prophylactic cranial irradiation in operable stage IIIa non-small cell lung cancer treated with neoadjuvant chemoradiotherapy: results from a German Multicenter randomized trial. J. Clin. Oncol.31, 4987–4992 (2007).
   Google Scholar
• Auperin A, Arriagada R, Pignon JP et al. Prophylactic cranial irradiation for patients with small cell lung cancer in complete remission. N. Engl. J. Med.341, 476–484 (1999).
   PubMed Web of Science ®Google Scholar
• Slotman B, Faivre-Finn C, Kramer G et al. Prophylactic cranial irradiation in extensive small cell lung cancer. N. Engl. J. Med.557, 664–672 (2007).
   Google Scholar
• Gregor A, Cull A, Stephens RJ et al. Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: results of a Multicenter randomized trial: United Kingdom Coordinating Committee for Cancer Research (UKCCCR) and the European Organization for research and treatment of Cancer (EORTC). Eur. J. Cancer33, 1752–1758 (1997).
   PubMed Web of Science ®Google Scholar
• Lin N, Bellon JR, Winer EP. CNS metastases in breast cancer. J. Clin. Oncol.22(17), 3608–3617 (2004).
   PubMed Web of Science ®Google Scholar
• Lin NU, Carey LA, Liu M et al. Phase II trial of lapatinib for brain metastases in patients with epidermal growth factor receptor-2 positive breast cancer. J. Clin. Oncol.12, 1993–1999 (2008).
   Google Scholar
• Burnstein HJ, Lieberman, Slamon DJ, Winer EP, Klein P. Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first line trastuzumab-based thrapy. Ann. Oncol.16, 1772–1777 (2005).
   Google Scholar
• Muller A, Homey B, Soto H et al. Involvement of chemokine receptors in breast cancer metastasis. Nature410, 50–56 (2001).
   PubMed Web of Science ®Google Scholar
• Hassan S, Ferrario C, Saragovi U et al. The influence of tumor–host interactions in the stromal cell-derived factor-1/CXCR4 ligand/receptor axis in determining metastatic risk in breast cancer. Am. J. Pathol.175(1), 66–73 (2009).
   Google Scholar
• Cabioglu N, Summy J, Miller Cet al. CXCL-12/stomal cell-derived factor-1 a transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation. Cancer Res.65(15), 6493–6497 (2005).
   PubMed Web of Science ®Google Scholar
• Li YM, Pan Y, Wei Y et al. Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell6(5), 429–430 (2004).
   Google Scholar
• Raizer JJ, Hwu WJ, Panageas KS et al. Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features. Neuro Oncol.2, 199–207 (2008).
   Google Scholar
• Tosoni A, Lumachi F, Brandes AA. Treatment of brain metastases in uncommon tumors. Expert Rev. Anticancer Ther.4(5), 783–793 (2004).
   PubMedGoogle Scholar
• Gabos Z, Sinha R, Hanson J et al. Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J. Clin. Oncol.24(36), 5658–5663 (2006).
   PubMed Web of Science ®Google Scholar
• Gaspar L, Scott C, Rotman M et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int. J. Radiat. Oncol. Biol. Phys.37, 745–751 (1997).
   PubMed Web of Science ®Google Scholar
• Lagerwaard FJ, Levendag PC, Nowak PJ, Eijkenboom WM, Hanssens PE, Schmitz PI. Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int. J. Radiat. Oncol. Biol. Phys.43(4), 795–803 (1999).
   PubMed Web of Science ®Google Scholar
• Sperduto CM, Watanabe Y, Mullan J et al. A validation study of a new prognostic index for patients with brain metastases: the graded prognostic assessment. J. Neurosurg.109(Suppl.), 87–89 (2008).
   PubMedGoogle Scholar
• Sanghavi SN, Muranpuri SS, Chappell R et al. 48 Multi-institutional survival analysis of brain metastases patients treated with radiosurgery, stratefied by RTOG RPA classification. Int. J. Radiat. Oncol. Biol. Phys.45(3), 171–178 (1999).
   Google Scholar
• Lesser GT. Chemotherapy of cerebral metastases from solid tumors. Neurosurg. Clin. N. Am.7(3), 527–536 (1996).
   PubMed Web of Science ®Google Scholar
• Peereboom DM. Chemotherapy in brain metastases. Neurosurgery57(5 Suppl.), S54–S65 (2005).
   Google Scholar
• Vecht CJ, Hovestadt A, Verbiest HBC, van Vliet JJ, van Putten WLJ. Dose effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8 and 16mg per day. Neurology44, 675–680 (1994).
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Taylor LP, Thaler HT, Posner JB, DeAngelis LM. Steroid myopathy in cancer patients. Neurology48(5), 1234–1238 (1997).
   PubMed Web of Science ®Google Scholar
• Glantz MJ, Cole BF, Forsyth PA et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology54(10), 1886–1893 (2000).
   PubMed Web of Science ®Google Scholar
• Fetell MR, Grossman SA, Fisher JD et al. Pre-irradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions: new approaches to brain tumor therapy. Central Nervous System Consortium. J. Clin. Oncol.15(9), 3121–3128 (1997).
   PubMedGoogle Scholar
• Vecht C, Haaxma-Reiche H, Noordijk E et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery. Ann. Neurol.33, 583–590 (1993).
   PubMed Web of Science ®Google Scholar
• Patchell R, Tibbs P, Walsh J et al. A randomized trial of surgery in the treatment of single metastases to the brain. N. Engl. J. Med.322, 494–500 (1990).
   PubMed Web of Science ®Google Scholar
• Patchell R, Regine W, Loeffler J et al. Radiosurgery plus whole-brain radiation therapy for brain metastases. JAMA Lett.296, 2089–2090 (2006).
   Google Scholar
• Bindal R, Sawaya R, Leavens M et al. Surgical treatment of multiple brain metastases. J. Neurosurg.79, 210–216 (1993).
   PubMed Web of Science ®Google Scholar
• Bindal R, Sawaya R, Leavens M et al. Reoperation for recurrent metastatic brain tumors. J. Neurosurg.83, 600–604 (1995).
   PubMed Web of Science ®Google Scholar
• Rades D, Kieckebusch S, Haatanen T et al. Surgical resection followed by whole brain radiotherapy alone for single brain metastasis. Int. J. Radiat. Oncol. Biol. Phys.70(5), 1319–1324 (2008).
   Google Scholar
• Mintz AH, Kestle J, Rathbone MP et al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastases. Cancer78(7), 1470–1746 (1996).
   PubMed Web of Science ®Google Scholar
• Ewend MG, Brem S, Gilbert M et al. Treatment of single brain metastasis with resection, intracavity carmustine polymer wafers, and radiation therapy is safe and provides excellent local control. Clin. Cancer Res.13(12), 3637–3641 (2007).
   PubMed Web of Science ®Google Scholar
• Vogelbaum MA, Suh JH. Resectable brain metastases. J. Clin. Oncol.24(8), 1289–1294 (2006).
   Google Scholar
• Weinberg JS, Lang FF, Sawaya R. Surgical management of brain metastases. Curr. Oncol. Rep.3(6), 476–483 (2001).
   PubMedGoogle Scholar
• Nussbaum ES, Djalilian HR, Cho KH, Hall WA. Brain metastases. Histology, multiplicity, surgery, and survival. Cancer78(8), 1781–1788 (1996).
   PubMed Web of Science ®Google Scholar
• Patchell RA, Tibbs PA, Regine WF et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA280(17), 1485–1489 (1998).
   PubMed Web of Science ®Google Scholar
• Andrews DW, Scott CB, Sperduto PW et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: Phase III results of the RTOG 9508 randomised trial. Lancet363(9422), 1665–1672 (2004).
   PubMed Web of Science ®Google Scholar
• Lo S, Chang E, Suh J. Stereotactic radiosurgery with and without whole-brain radiotherapy for newly diagnosed brain metastases. Expert Rev. Neurother.5(4), 487–495 (2005).
   PubMedGoogle Scholar
• Sneed PK, Lamborn KR, Forstner JM et al. Radiosurgery for brain metastases: is whole brain radiotherapy necessary? Int. J. Radiat. Oncol. Biol. Phys.43, 549–558 (1999).
   PubMed Web of Science ®Google Scholar
• Sneed PK, Suh JH, Goetsch SJ et al. A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastases. Int. J. Radiat. Oncol. Biol. Phys.53(3), 519–526 (2002).
   PubMed Web of Science ®Google Scholar
• Aoyama H, Shirato H, Tago M et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs. stereotactic radiosurgery alone for treatment of brain metastases. JAMA295, 2483–2491 (2006).
   PubMed Web of Science ®Google Scholar
• Samlowski WE, Watson GA, Wang M et al. Multimodality treatment of melanoma brain metastases incorporating stereotactic radiosurgery (SRS). Cancer109(9), 1855–1862 (2007).
   PubMed Web of Science ®Google Scholar
• Hara W, Tran P, Li G et al. Cyberknife for brain metastases of malignant melanoma and renal cell carcinoma. Neurosurgery.64(2 Suppl.), A26–A32 (2009).
   Google Scholar
• Manon R, O’Neill A, Knisely J et al.; Eastern Cooperative Oncology Group. Phase II trial of radiosurgery for one to three newly diagnosed brain metastases from renal cell carcinoma, melanoma, and sarcoma: an Eastern Cooperative Oncology Group study (E 6397). J. Clin. Oncol.23(34), 8870–8876 (2005).
   PubMed Web of Science ®Google Scholar
• Chougule PB. Concepts and controversies in the treatment of brain metastases. Med. Health R I79(6), 214–217 (1996).
   Google Scholar
• Suh JH, Stea B, Nabid A et al. Phase III study of efaproxiral as an adjunct to whole brain radiation therapy for brain metastases. J. Clin. Oncol.24(1), 106–114, (2006).
   PubMed Web of Science ®Google Scholar
• Brown P, Asher A, Farice E. Adjuvant whole brain radiotherapy: strong emotions decide but rationale studies are needed. Int. J. Radiat. Oncol. Biol. Phys.70, 1305–1309 (2008).
   Google Scholar
• Arbit E, Wroński M, Burt M, Galicich JH. The treatment of patients with recurrent brain metastases. A retrospective analysis of 109 patients with non-small cell lung cancer. Cancer76(5), 765–773 (1995).
   PubMed Web of Science ®Google Scholar
• Platta CS, Khuntia D, Mehta MP, Suh JH. Current treatment strategies for brain metastasis and complications from therapeutic techniques: a review of current literature. Am J. Clin. Oncol. doi: 10.1097/COC.0b013e318194f744 (2009) (Epub ahead of print).
   Google Scholar
• Chao ST, Barnett GH, Vogelbaum MA et al. Salvage stereotactic radiosurgery effectively treats recurrences from whole-brain radiation therapy. Cancer113(8), 2198–2204 (2008).
   PubMed Web of Science ®Google Scholar
• Kondziolka D, Patel A, Lunsford LD, Kassam A, Flickinger JC. Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int. J. Radiat. Oncol. Biol. Phys.45(2), 427–434 (1999).
   PubMed Web of Science ®Google Scholar
• DeAngelis LM, Mandell LR, Thaler HT et al. The role of postoperative radiotherapy after resection of single brain metastases. Neurosurgery24, 798–805 (1989).
   PubMed Web of Science ®Google Scholar
• Regine W, Scott C, Murray K et al. Neurocognitive outcome in brain metastases patients treated with accelerated fractionation vs. accelerated hyperfractionated radiotherapy: an analysis from Radiation Therapy Oncology Group 91-104. Int. J. Radiat. Oncol. Biol. Phys.51(3), 711–717 (2001).
   PubMed Web of Science ®Google Scholar
• Aoyama H, Tago M, Katoh N et al. Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. Int. J. Radiat. Oncol. Biol. Phys.68, 1388–1395 (2007).
   PubMed Web of Science ®Google Scholar
• Li J, Bentzen SM, Renschler M, Mehta M. Regression after whole brain radiation therapy for brain metastases correlates with survival and improved neurocognitive outcome. J. Clin. Oncol.25(10), 1260–1266 (2007).
   PubMed Web of Science ®Google Scholar
• Meyers CA, Smith JA, Bezjak A et al. Neurocognitive function and progression in patients with brain metastases treated with whole brain radiation and motexafin gadolinium: results of a randomized Phase III trial. J. Clin. Oncol.22(1), 157–165 (2004).
   PubMed Web of Science ®Google Scholar
• Mehta MP, Rodrigus P, Terhaard CH et al. Survival and neurological outcomes in a randomized trial of motexafin gadolinium and whole brain radiation therapy in brain metastases. J. Clin. Oncol.21, 2529–2536 (2003).
   PubMed Web of Science ®Google Scholar
• Regine WF, Schmitt FA, Scott CD et al. Feasibility of neurocognitive outcome evaluations in patients with brain metastases in a multi-institutional cooperative group setting: results of radiation therapy oncology group trial BR-0018. Int. J. Rad. Oncol. Biol. Phys.58(5), 1346–1352 (2004).
   PubMed Web of Science ®Google Scholar
• Shaw E, Scott C, Suh J et al. RSR13 plus cranial radiation therapy in patients with brain metastases: Comparison with Radiation Therapy Oncology Group Recursive Partitioning Analysis brain metastases database. J. Clin. Oncol.21(12), 2364–2371 (2003).
   PubMed Web of Science ®Google Scholar
• Regine W, Huhn J, Patchell R et al. Risk of symptomatic brain tumor recurrence and neurologic deficit after radiosurgery alone in patients with newly diagnosed brain metastases: results and implications. Int. J. Radiat. Oncol. Biol. Phys.52(2), 333–338 (2002).
   PubMed Web of Science ®Google Scholar
• Abrey LE, Olson JD, Raizer JJ et al. A Phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J. Neurooncol.53, 259–265 (2001).
   PubMed Web of Science ®Google Scholar
• Christodoulou C, Bafaloukos D, Kosmidis P et al. Phase II study of temozolomide in heavily pretreated cancer patients with brainmetastases. Ann. Oncol.12, 249–254 (2001).
   PubMed Web of Science ®Google Scholar
• Antondou D, Paraskevaidis M, Sarris G et al. Phase II randomized trial of temozolomide concurrent radiotherapy in patients with brain metastases. J. Clin. Oncol.20, 3644–3650 (2002).
   Google Scholar
• Agarwala SS, Kirkwood JM, Gore M. Temozolomide for the treatment of brain metastasis associated with metastatic melanoma. J. Clin. Oncol.22, 2101–2107 (2004).
   PubMed Web of Science ®Google Scholar
• Adamo V, Franchina T, Adamo B, Scandurra G, Scimone A. Brain metastases in patients with non-small lung cancer: focus on the role of chemotherapy. Ann. Oncol.17(Suppl. 2), ii73–ii75 (2006).
   PubMed Web of Science ®Google Scholar
• Greig NH. Chemotherapy of brain metastases: current status. Cancer Treat.Rev.11, 157–186 (1984).
   PubMed Web of Science ®Google Scholar
• Bearz A, Garassino I, Tiseo M et al. Activity of pemetrexed on brain metastases from non-small-cell lung cancer. Lung Cancer doi:10.1016/j.luncan.2009.06.018 (2009) (Epub ahead of print).
   Google Scholar
• Bernardo G, Cuzzoni Q, Strada MR et al. First-line chemotherapy with vinorelbine, gemcitabine, and carboplatin in the treatment of brain metastases from non-small-cell lung cancer: a Phase II study. Cancer Invest.20, 293–302 (2002).
   PubMed Web of Science ®Google Scholar
• Ceresoli G, Cappuzzo F, Gregorc V et al. Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann. Oncol.15(7), 1042–1047 (2004).
   PubMed Web of Science ®Google Scholar
• Robinet G, Thomas P, Breton JL et al. Results of a Phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Franccais de Pneumo-Canceerologie (GFPC) Protocol 95–91. Ann. Oncol.12(1), 59–67 (2001).
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Ardizzoni A, Soto-Parra H et al. Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases fron non-small-cell lung cancer (NSCLC). Lung Cancer41, 227–231 (2003).
   PubMed Web of Science ®Google Scholar
• Seute T, Leffers P, Wilmink JT, ten Velde GPM, Twijnstra A. Response of asymptomatic brain metastases from small-cell lung cancer to systemic first-line chemotherapy. J. Clin. Oncol.24(13), 2079–2083 (2006).
   PubMed Web of Science ®Google Scholar
• Boogerd W, Dalesio O, Bais EM, van der Sande JJ. Response of brain metastases from breast cancer to systemic chemotherapy. Cancer69(4), 972–980 (1992).
   PubMed Web of Science ®Google Scholar
• Soffetti R, Mueller RP, Abacioglu MU et al. Adjuvant whole brain radiotherapy versus observation after radiosurgery or surgical resection of 1–3 cerebral metastases – results of the EORTC 22952–26001 study. Neuro Oncol.11(5), 662 (2009) (Abstract 433).
   Google Scholar
• Muacevic A, Wowra B, Siefert A et al. Microsurgery plus whole brain irradiation versus gamma knife surgery alone for treatment of single metastases to the brain: a randomized controlled multicentre Phase III trial. J. Neurooncol87, 299–307 (2008).
   PubMed Web of Science ®Google Scholar